Definitive Healthcare (NASDAQ:DH) Rating Increased to Strong-Buy at Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

Other equities research analysts have also issued reports about the company. Morgan Stanley reiterated an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a research note on Thursday. Canaccord Genuity Group lowered their price target on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, October 8th. Barclays decreased their price objective on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a report on Monday, December 8th. Finally, William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Definitive Healthcare has a consensus rating of “Hold” and a consensus target price of $3.94.

Definitive Healthcare Trading Down 1.6%

Shares of NASDAQ:DH opened at $2.54 on Friday. The business’s 50 day moving average price is $2.71 and its 200-day moving average price is $3.47. Definitive Healthcare has a 1 year low of $2.15 and a 1 year high of $5.68. The firm has a market capitalization of $359.05 million, a price-to-earnings ratio of -1.52 and a beta of 1.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.60 and a quick ratio of 1.60.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $60.05 million for the quarter, compared to the consensus estimate of $59.51 million. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. On average, equities research analysts forecast that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Trading of Definitive Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. New York State Common Retirement Fund lifted its holdings in Definitive Healthcare by 0.4% in the second quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock valued at $2,989,000 after acquiring an additional 3,066 shares during the last quarter. BNP Paribas Financial Markets raised its position in Definitive Healthcare by 32.9% in the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after purchasing an additional 4,407 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Definitive Healthcare in the 2nd quarter valued at $32,000. Creative Planning grew its holdings in shares of Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after purchasing an additional 8,428 shares during the period. Finally, Farther Finance Advisors LLC acquired a new stake in shares of Definitive Healthcare during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.